Evaxion Biotech A/S
EVAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $0 | $0 | $0 |
| % Growth | 4,480.8% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3 | $0 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $10 | $12 | $17 | $20 |
| G&A Expenses | $7 | $10 | $8 | $6 |
| SG&A Expenses | $7 | $10 | $8 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $18 | $22 | $25 | $26 |
| Operating Income | -$15 | -$22 | -$25 | -$26 |
| % Margin | -440.6% | -30,406.8% | – | – |
| Other Income/Exp. Net | $3 | -$1 | $1 | $1 |
| Pre-Tax Income | -$11 | -$23 | -$24 | -$25 |
| Tax Expense | -$1 | -$1 | -$1 | -$0 |
| Net Income | -$11 | -$22 | -$23 | -$25 |
| % Margin | -316% | -30,308.2% | – | – |
| EPS | -9.8 | -32.4 | -39.2 | -50.4 |
| % Growth | 69.8% | 17.3% | 22.2% | – |
| EPS Diluted | -9.8 | -32.4 | -39.2 | -50.4 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $3 | $2 |
| Interest Expense | $1 | $1 | $2 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$10 | -$21 | -$23 | -$24 |
| % Margin | -292.6% | -29,319.2% | – | – |